HCA Healthcare, Inc. — Initiating Coverage

Download Financial Model (PDF)

---

Investment Summary

We are initiating coverage of HCA Healthcare (NYSE: HCA) with a Buy rating and a price target of $542.90, representing approximately ~39.3% upside from the July 27, 2026 closing price of $389.62. Our price target is derived exclusively from our DCF framework: a probability-weighted average of three scenarios weighted 25% bear, 50% base, and 25% bull, with a 10% margin of safety applied to the probability-weighted result. Peer-multiple cross-checks (EV/Revenue, EV/EBITDA, EV/EBIT, and P/E) are presented separately as a market-sentiment sanity check and are not blended into the target price. At 39.3% implied upside, HCA clears our 10% Buy threshold by a wide margin. Our rating framework defines Buy as implied upside above 10%, Hold as negative 10% to positive 10%, and Sell as implied downside exceeding 10%.

Our buy thesis rests on three observations: (1) HCA is the best-in-class large-cap hospital operator by virtually every operating metric, with scale, local market density in high-growth Sun Belt geographies, and a management team with a long track record of execution that constitute genuine, durable competitive advantages; (2) despite near-term headwinds from ACA Exchange subsidy expiration and Medicaid supplemental payment program restructuring, our base-case model already conservatively incorporates these dynamics and still produces 57.0% upside to the pre-MoS base-case intrinsic value, meaning the headwinds are reflected in our assumptions and the business remains fundamentally sound; and (3) HCA's aggressive share buyback program ($10.07 billion in FY2025, $10 billion authorized for 2026) is systematically shrinking the share count in a way our static model does not capture, meaning our $542.90 target is conservative relative to what a buyback-adjusted per-share intrinsic value would produce.

The 10% margin of safety applied to the pre-MoS probability-weighted value of $603.23 reflects valuation uncertainty inherent in a highly leveraged, reimbursement-dependent business with meaningful ACA and Medicaid policy risk over the projection horizon. We would reassess toward Hold if the current price appreciated toward $603.23, narrowing the margin of safety, or if ACA headwinds materialize materially worse than our bear-case assumptions. Upward revision to our price target would be warranted if FY2026 EBITDA margin holds above our 20.1% base-case assumption or if HCA discloses material progress on AI-driven efficiency initiatives not currently reflected in our UFCF projections.

---

Company Overview

Business Description

HCA Healthcare is the largest for-profit hospital operator in the United States, with 190 hospitals encompassing approximately 50,436 licensed beds and over 2,400 outpatient facilities as of December 31, 2025. The company operates across 19 U.S. states and England, with a concentrated presence in high-growth Sun Belt markets. HCA generated $75.6 billion in revenue in FY2025, making it one of the largest healthcare companies in the world by revenue.

The company operates across three primary service lines: inpatient hospital services (acute care, behavioral health, rehabilitation), outpatient services (ambulatory surgery centers, endoscopy centers, imaging, urgent care), and physician practice management. Revenue is derived from a mix of government and commercial payers, with commercial and managed care insurance representing the largest and highest-margin category at approximately 48.9% of FY2025 revenue.

Geographic Concentration

The most structurally important fact about HCA's footprint is its concentration in Florida and Texas, which together accounted for approximately 51% of consolidated FY2025 revenue and house 102 of the company's 190 hospitals. This reflects a deliberate strategy of building dominant local market share in the fastest-growing large states in the country by population and employment. The same concentration that drives above-industry growth also creates idiosyncratic exposure to Florida- and Texas-specific Medicaid policy, regulatory changes, and weather events.

Payer Mix

HCA's payer mix is materially more favorable than the average U.S. hospital system, which is a key driver of its margin premium over peers. FY2025 revenue by payer: commercial and managed care insurers 48.9%, managed Medicare 17.8%, traditional Medicare 14.9%, Medicaid 7.8%, managed Medicaid 4.9%, international 2.5%, and other 3.2%. The near-absence of uncompensated care and the heavy commercial weighting are the primary structural reasons HCA generates EBITDA margins above 20% while the broader hospital industry averages are substantially lower.

Capital Allocation Philosophy

HCA operates with a deliberately leveraged balance sheet and an aggressive share buyback program. The company repurchased $10.07 billion of its own shares in FY2025, $6.04 billion in FY2024, and $3.81 billion in FY2023, with a $10 billion authorization in place as of January 2026. The result is negative shareholders' equity of approximately -$6.0 billion at year-end 2025, total financial debt of $46.5 billion, and diluted EPS growth that consistently outpaces net income growth as the share count shrinks. This is capital discipline in the sense that management is returning cash rather than empire-building, but it also means leverage is structurally elevated by design, leaving less room for error in a downside scenario than a company with a conventional balance sheet would have.

---

Industry & Competitive Landscape

U.S. Hospital Industry Dynamics

The U.S. hospital industry is a regulated, reimbursement-dependent business operating at the intersection of demographic tailwinds and persistent policy risk. Demand is structurally growing: the U.S. population is aging, the 65-and-older cohort uses roughly four times the inpatient services of the under-65 population, and Sun Belt population growth is disproportionately concentrated in HCA's core geographies. These are durable tailwinds that should support above-GDP volume growth for well-positioned operators across the planning horizon.

At the same time, reimbursement is structurally constrained. Medicare rate increases are set annually by CMS and have historically trailed general medical cost inflation by 100 to 200 basis points. Medicaid reimbursement is set at the state level and is subject to budget cycles and federal policy changes, including the restructuring of supplemental payment programs that have historically provided material revenue to large hospital systems. The ongoing shift toward value-based care is an additional structural headwind, though likely a multi-decade transition rather than a near-term earnings risk.

Competitive Position

HCA's competitive position is built on three interlocking advantages that are genuinely difficult for new entrants or smaller operators to replicate:

• Scale and local market density: HCA holds leading or co-leading market share in the majority of the metropolitan areas it serves. Scale drives more favorable payer contract terms, better physician recruiting leverage, and the ability to amortize fixed technology and administrative costs across a larger revenue base.

• Certificate-of-need regulatory barriers: Many of HCA's core states have CON laws that require regulatory approval for new hospital capacity. While CON laws are not an impenetrable barrier, they meaningfully slow competitive entry and have historically protected established operators from greenfield competition in their core markets.

• Sun Belt demographic positioning: Florida and Texas have above-average population growth driven by domestic in-migration and international immigration, above-average commercial insurance penetration, and relatively favorable state-level regulatory environments for investor-owned hospital systems.

Near-Term Headwinds

The 2026 environment introduces several specific headwinds. The expiration of enhanced Affordable Care Act premium tax credits is reducing ACA Exchange enrollment and creating both volume and payer mix pressure. Medicaid supplemental payment program restructuring under the FY2026 federal budget act is expected to reduce supplemental revenue in certain states. Third-party physician professional fees continue to grow at high-single-digit rates, outpacing reimbursement rate increases and compressing facility-level margins. These headwinds are real, near-term, and partially quantifiable, and they are incorporated into our bear and base case operating assumptions.

---

Investment Thesis

Bull Case — $722.29 implied price. The bull case assumes FY2026E revenue of $79,002mm (+4.5%), gross margin of 41.5%, and a 10-year EBITDA margin trajectory starting at approximately 20.6% and expanding modestly as physician labor cost pressures normalize. WACC of 7.44% and terminal growth rate of 3.0% are applied. The bull scenario requires ACA-related volume headwinds to resolve faster than our base case and continued aggressive buyback execution that reduces the share count below our static 230.71mm assumption. Sensitivity range: $489.19 to $934.25.

Base Case — $678.19 implied price. The base case assumes FY2026E revenue of $78,624mm (+4.0%), gross margin of 41.5%, and EBITDA margin of approximately 20.1%, roughly in line with HCA's FY2025 actual of 20.6% with modest dilution from near-term cost pressures. WACC of 7.44% is built bottom-up: 4.485% risk-free rate (10-year U.S. Treasury), 4.18% equity risk premium (Damodaran implied), 1.13 levered beta. Pre-tax cost of debt of 5.10% weighted across the Senior Note stack. Equity weight 65.9%, debt weight 34.1% at current prices. Net financial debt of $45,452 million ($46,492 million gross less $1,040 million cash). Terminal growth rate of 3.0% reflects long-run nominal GDP growth adjusted for structural hospital volume headwinds from value-based care and payer mix pressure. Sensitivity range: $457.44 to $878.92.

Bear Case — $438.76 implied price. The bear case assumes FY2026E revenue of $78,246mm (+3.5%), gross margin of 40.0%, and a materially compressed EBITDA margin of approximately 17.1%, reflecting ACA Exchange volume declines larger than base, continued physician labor cost inflation, and Medicaid supplemental payment program cuts coming in at the high end of guided ranges. WACC of 7.44% and terminal growth rate of 3.0% are applied. Sensitivity range: $278.14 to $584.82.

Probability-weighting these three scenarios at 25% bear / 50% base / 25% bull produces a pre-MoS value of $603.23. Applying a 10% margin of safety yields our price target of $542.90, implying ~39.3% upside from the current price of $389.62. Our model conservatively holds shares outstanding flat at 230.71mm across all 10 projection years. Investors who model HCA's $10 billion annual buyback pace explicitly will arrive at a per-share intrinsic value materially above our target, as the shrinking share count amplifies the per-share benefit of compounding owner earnings.

---

Financial Analysis

The table below summarizes key financial metrics across the historical period and our FY2026 base-case projection. HCA's revenue has compounded at approximately 7% annually from FY2022 through FY2025, driven by a combination of equivalent admissions volume growth and revenue per equivalent admission pricing, with the FY2025 result of $75.6 billion (+7.1%) representing a particularly strong year aided by elevated ACA Exchange volumes and continued post-pandemic utilization normalization. FY2026E reflects a deliberate deceleration in our base case to 4.0%, incorporating the ACA subsidy expiration and Medicaid headwinds discussed in the investment thesis.

Revenue Model

FY2025 actual revenue of $75.6 billion is our projection anchor. Base-case FY2026E of $78.6 billion (+4.0%) reflects same-facility equivalent admissions volume growth of approximately 2% and revenue per equivalent admission pricing/mix contribution of approximately 2%, consistent with normalized trends but below the elevated FY2025 pace. Revenue growth decelerates through the 10-year projection window from 4.0% in FY2026E to 3.0% by FY2030E, as ACA-related volume headwinds normalize and organic expansion moderates with scale. Bear-case FY2026E of $78.2 billion (+3.5%) and bull-case FY2026E of $79.0 billion (+4.5%) reflect the range of plausible outcomes for ACA and Medicaid headwind resolution.

Margin Analysis

Our FY2026E base-case gross margin of 41.5% is anchored to the FY2025 actual of 41.5%, with modest downward pressure from physician labor cost inflation and payer mix pressure. EBITDA margin of 20.1% in the base case reflects this same pressure, partially offset by D&A reduction as a percentage of revenue as the capital intensity of HCA's facility base stabilizes. Bear-case EBITDA margin of approximately 17.1% reflects a scenario where physician labor inflation and ACA/Medicaid headwinds compound simultaneously.

Capital Expenditure

HCA's CapEx intensity has run at approximately 6.5 to 6.9% of revenue historically. Our base-case FY2026E CapEx of approximately $5.4 billion (6.9% of revenue) assumes maintenance of current investment pace, declining toward approximately 5.9% of revenue by FY2035E as the capital program matures. CapEx is the primary free cash flow swing factor given the relative stability of the operating income line, and modestly higher or lower CapEx intensity materially changes the UFCF generation available to the DCF.

---

Valuation

Price Target Methodology

Our price target of $542.90 is derived from a probability-weighted average of three DCF scenarios (25% bear / 50% base / 25% bull), with a 10% margin of safety applied to the probability-weighted result of $603.23. WACC is held constant at 7.44% across all three scenarios. The terminal growth rate of 3.0% is also held constant across all three scenarios, with scenario differentiation driven entirely by the operating assumptions: revenue growth, gross margin, SG&A, and CapEx. The 10% margin of safety reflects the inherent uncertainty in projecting a highly leveraged, reimbursement-dependent business across a 10-year horizon with meaningful policy risk on both the revenue and cost sides.

DCF Scenario Summary

DCF Methodology

Our primary valuation methodology is a 10-year unlevered free cash flow (UFCF) model with a Gordon Growth Model terminal value. UFCF is defined as NOPAT (EBIT × (1 - tax rate)) plus D&A, less capital expenditures and changes in net working capital. The model is capital-structure-neutral at the cash-flow stage; the capital structure enters through WACC at the discount-rate stage and through net financial debt at the equity bridge. Operating lease liabilities are treated as operating costs within EBIT rather than financial debt, consistent with UFCF convention.

Our 10-year DCF holds diluted shares outstanding constant at 230.71mm. Given HCA's stated $10 billion annual buyback pace, this is a deliberately conservative assumption. Investors who model the buyback trajectory explicitly will arrive at a per-share intrinsic value materially above our $542.90 target.

WACC Derivation

Terminal value as a percentage of enterprise value (80.4% bear, 80.3% base, 80.7% bull) is meaningfully higher than in our DKS analysis (38 to 40%), reflecting HCA's more capital-intensive, mature business where near-term free cash flow is partially offset by elevated CapEx. The higher terminal value weighting increases sensitivity to WACC and TGR assumptions, which is the primary driver of the wide sensitivity ranges.

Sensitivity Analysis: Base Case

The table below shows base-case DCF-derived implied share prices across a WACC and TGR grid. The highlighted cell at 7.44% WACC / 3.0% TGR is the base-case central estimate of $635 (pre-MoS). The wide range from $457 to $879 reflects HCA's high terminal value weighting and the mathematical sensitivity of the Gordon Growth terminal value where the denominator (WACC minus TGR) narrows.

Highlighted cell = base-case central estimate (pre-MoS). Price target of $542.90 reflects 10% MoS applied to probability-weighted average of all three scenarios.

Comparable Company Analysis

We present a five-peer comparable company analysis using NTM multiples. No pure-play acute-care hospital operator of comparable scale exists, so the peer set includes diversified facility operators whose operating models differ from HCA's in meaningful ways. We use peer median rather than peer mean to limit distortion from outliers, and exclude CYH from the P/E median calculation given its near-zero NTM EPS ($0.11), which reflects earnings distress rather than a meaningful valuation reference.

¹ CYH P/E excluded from median due to near-zero EPS reflecting distressed earnings. ² Median of THC (11.0x), UHS (6.1x), EHC (16.6x), DVA (9.8x).

Multiples Cross-Check (Not a Target Price Input)

All four peer-median multiples imply share prices below the current price, ranging from $191 (EV/EBITDA) to $353 (P/E). This reflects that our peer set trades at multiples substantially below where HCA has historically commanded a premium. At 8.0 to 9.7x EV/EBITDA, a range more consistent with best-in-class operator premiums, the implied share price would range from approximately $317 to $494.

---

Key Risks

Downside Risks

• ACA Exchange and Medicaid Headwinds (HIGH): The expiration of enhanced ACA premium tax credits and restructuring of Medicaid supplemental payment programs represent the single most significant near-term earnings risk. The bear case assumes these headwinds come in at the high end of guidance, compressing both volume and payer mix and producing FY2026E revenue of only $78.2 billion versus our base case of $78.6 billion.

• Physician Labor Cost Inflation: Third-party physician professional fees are growing at high-single-digit rates, driven by persistent labor shortages in specialty clinical labor. This cost category does not respond to traditional labor market normalization at the same pace as contract nursing labor, and represents a multi-year margin headwind if not offset by reimbursement rate increases.

• Florida and Texas Geographic Concentration: 51% of consolidated revenue is concentrated in two states. State-specific Medicaid policy changes, regulatory shifts, or weather events (hurricanes in Florida particularly) create idiosyncratic risk that a more geographically diversified operator would not face.

• Leverage and Negative Shareholders' Equity: $45.5 billion in net financial debt and negative equity create meaningful downside amplification in a stressed scenario. In our bear case the implied equity value of $438.76 still represents approximately 7.5% upside from current prices, reflecting strong underlying business quality even in an adverse scenario.

• Value-Based Care as a Long-Term Structural Headwind: As more physician payments tie to outcomes and reduced readmissions, inpatient volume growth is structurally pressured over the long run. This is the primary reason our terminal growth rate of 3.0% is at or below nominal GDP growth estimates.

• Reimbursement Rate Risk: Annual Medicare rate updates have historically trailed medical cost inflation. CMS increased MS-DRG payment rates by approximately 2.6% for federal fiscal year 2026, below general medical cost inflation, creating margin pressure that must be offset by commercial contract rate increases.

Upside Risks

• ACA Headwind Resolution Faster Than Expected: If ACA Exchange enrollment declines prove more modest than guided, or if Medicaid supplemental program restructuring is phased in more slowly, FY2026 revenue and margin could track closer to our bull-case assumptions. This is the single most actionable upside catalyst for the near-term investment case.

• Share Buyback Accretion Exceeds Static Assumption: Our model holds diluted shares at 230.71 million throughout the 10-year projection window. At HCA's historical $8 to $10 billion annual pace, the actual share count at year-end 2035 would be materially lower, driving per-share intrinsic value above our target without any change in operating assumptions.

• Sun Belt Population Growth Secular Tailwind: Texas and Florida continue to attract domestic in-migration and international immigration at above-national rates. If this demographic tailwind sustains above-industry equivalent admissions volume growth, the base-case revenue growth trajectory could be too conservative in the outer projection years.

• Physician Labor Normalization: If specialist labor market conditions ease in 2027 and beyond, high-single-digit growth in professional fees could decelerate, restoring facility-level margins toward the FY2025 baseline.

• AI-Driven Efficiency Optionality: HCA is investing in AI-driven clinical efficiency and administrative automation. None of these investments are attributed standalone value in our UFCF model. Material efficiency gains would represent incremental upside not captured in our projection.

---

Recommendation

We initiate coverage of HCA Healthcare (NYSE: HCA) with a Buy rating and a price target of $542.90, derived from a probability-weighted average of our three DCF scenarios (25% bear / 50% base / 25% bull) with a 10% margin of safety applied to the pre-MoS probability-weighted value of $603.23. At the current price of $389.62, the implied upside of ~39.3% clears our 10% Buy threshold by a wide margin under a rating framework that defines Buy as implied upside above 10%, Hold as negative 10% to positive 10%, and Sell as implied downside exceeding 10%.

HCA is the dominant hospital operator in the United States, with best-in-class margins, a management team with a decades-long track record of execution, and a geographic concentration in the two fastest-growing large states in the country. The scale premium that allows HCA to negotiate better managed care contracts, recruit more selectively, and amortize fixed costs across a larger revenue base compounds over time. The Sun Belt demographic tailwind directly supports the equivalent admissions volume trajectory embedded in our base case.

Near-term headwinds from ACA Exchange subsidy expiration and Medicaid supplemental program restructuring are already conservatively incorporated into our base-case and bear-case operating assumptions. WACC is held constant at 7.44% across all three scenarios, with scenario differentiation driven entirely by operating assumptions. The 10% margin of safety appropriately reflects the uncertainty inherent in projecting a highly leveraged business across a 10-year horizon with meaningful policy risk.

HCA's aggressive capital return program — $10 billion in annual buybacks against a current market cap of approximately $89.9 billion — is retiring more than 10% of its own equity annually. Every dollar of that buyback at current prices adds to per-share intrinsic value in a way that our static-share-count model does not capture. Our $542.90 target is conservative on this dimension.

Current holders should maintain positions. New investors should initiate at current levels, where the 39.3% implied upside to our price target clears the Buy threshold by a wide margin, and the pre-MoS base-case intrinsic value of $678 implies considerably greater upside for investors who apply a smaller or no margin of safety to this business quality.